TxCell is exclusively developing regulatory T cells that are specific of a single antigen.
As shown below, our general process starts with a simple leukapheresis. From this sample, we produce antigen-specific Treg cells and then expand them before injecting them back to the patient.
Our platform has the potential to address a wide range of severe inflammatory and autoimmune disorders with unmet medical needs. TxCell’s current targets include transplant rejection, multiple sclerosis, inflammatory bowel diseases such as Crohn’s disease, lupus nephritis and skin diseases such as bullous pemphigoid.
The antigen specificity comes from the CAR receptor as shown below.
After their isolation from the blood of patients, Treg cells are genetically modified by transduction with Chimeric Antigen Receptors (CAR). The CAR introduced into Treg cells is designed to allow Treg cell activation and immuno-modulation through in vivo recognition of a protein present in inflamed areas in patients suffering from autoimmune and chronic inflammatory diseases.
TxCell has initiated more than 10 CAR-Treg development programs. Initially, TxCell is focusing its resources on four to five CAR-Treg programs targeting notably transplant rejection, multiple sclerosis, lupus nephritis and bullous pemphigoid.
TxCell’s objectives are: firstly, to generate regularly additional preclinical proof-of-concept data and, secondly, to start at least one first-in-man clinical study before the end of 2018. A number of these programs are being developed through collaboration agreements with leading international academic laboratories, such as the University of British Columbia (UBC) in Canada, Ospedale San Raffaele (OSR) in Italy and the Lübeck Institute of Experimental Dermatology (LIED) in Germany.